Jeil Pharma Holdings Inc (KRX:002620)
South Korea flag South Korea · Delayed Price · Currency is KRW
8,210.00
+70.00 (0.86%)
At close: Feb 20, 2026

Jeil Pharma Holdings Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
689,545769,968794,714787,256756,633755,330
Other Revenue
17,6099,8559,3295,7085,9356,667
707,153779,822804,043792,965762,568761,997
Revenue Growth (YoY)
-9.20%-3.01%1.40%3.99%0.07%4.13%
Cost of Revenue
459,110573,301589,459612,482582,061570,757
Gross Profit
248,044206,521214,584180,483180,507191,239
Selling, General & Admin
170,308158,410146,364146,465149,808144,028
Research & Development
39,85438,95046,03841,56639,67324,731
Other Operating Expenses
1,84520,7191,363---
Operating Expenses
211,707217,702193,664188,031189,482169,236
Operating Income
36,336-11,18120,920-7,548-8,97522,003
Interest Expense
-7,640-8,875-10,672-5,952-3,289-3,194
Interest & Investment Income
2,4042,4564,119508.95256.81179.62
Earnings From Equity Investments
808.35---2,516623.76
Currency Exchange Gain (Loss)
1,1373,019-169.48314.8816.09-722.45
Other Non Operating Income (Expenses)
84.79-7,435-2,492856.19-2,864344.45
EBT Excluding Unusual Items
33,129-22,01611,706-11,820-11,53919,235
Impairment of Goodwill
-44,862-44,862-28,604-78,335-17,014-
Gain (Loss) on Sale of Investments
6,2805,9072,9237,12720,87616,146
Gain (Loss) on Sale of Assets
13.837.970.5323.981,9306.69
Asset Writedown
-662.52-662.52-7.42-856.39-382-4,566
Pretax Income
-6,102-61,626-13,982-83,861-6,12930,822
Income Tax Expense
4,5264,765-740.82-715.626,74115,881
Earnings From Continuing Operations
-10,627-66,391-13,241-83,145-12,87014,941
Net Income to Company
-10,627-66,391-13,241-83,145-12,87014,941
Minority Interest in Earnings
-18,78515,232-3,0098,5899,388-3,510
Net Income
-29,412-51,159-16,250-74,556-3,48211,431
Net Income to Common
-29,412-51,159-16,250-74,556-3,48211,431
Shares Outstanding (Basic)
151515151515
Shares Outstanding (Diluted)
151515151515
Shares Change (YoY)
-0.03%-----
EPS (Basic)
-1916.24-3332.61-1058.54-4856.70-226.85744.64
EPS (Diluted)
-1916.63-3333.00-1059.00-4857.00-227.00744.64
Free Cash Flow
-7,180202.38-10,638-32,717-10,284-33,482
Free Cash Flow Per Share
-467.8013.18-692.99-2131.27-669.95-2181.10
Dividend Per Share
50.00050.00050.00050.00065.00070.000
Dividend Growth
----23.08%-7.14%-
Gross Margin
35.08%26.48%26.69%22.76%23.67%25.10%
Operating Margin
5.14%-1.43%2.60%-0.95%-1.18%2.89%
Profit Margin
-4.16%-6.56%-2.02%-9.40%-0.46%1.50%
Free Cash Flow Margin
-1.01%0.03%-1.32%-4.13%-1.35%-4.39%
EBITDA
51,0092,91833,4763,3578.3130,654
EBITDA Margin
7.21%0.37%4.16%0.42%0.00%4.02%
D&A For EBITDA
14,67314,09912,55610,9058,9838,651
EBIT
36,336-11,18120,920-7,548-8,97522,003
EBIT Margin
5.14%-1.43%2.60%-0.95%-1.18%2.89%
Effective Tax Rate
-----51.52%
Advertising Expenses
-9,5975,9296,2288,74210,675
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.